Literature DB >> 20065648

Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.

Yin Luo1, Zhaojiang Lu, Stephen W Raso, Clifford Entrican, Bruce Tangarone.   

Abstract

The in vitro binding of monomeric, dimeric and multimeric forms of monoclonal IgG1 molecules, designated mAb1 and mAb2, to the extracellular domains of Fcgamma receptors RI, RIIA and RIIIB were investigated using a surface plasmon resonance (SPR) based biosensor technique. Stable noncovalent and covalent dimers of mAb1 and mAb2, respectively, were isolated from CHO cell expressed materials. The dissociation constants of monomeric mAb1 and mAb2 were determined to be 1 nM for the FcgammaRI-binding and 6-12 microM for the FcgammaRIIA- and FcgammaRIIIB-binding. Dimeric mAb1 and mAb2 exhibited increased affinities, by 2-3 fold for FcgammaRI and 200-800 fold for FcgammaRIIA and FcgammaRIIIB. Further increases in binding were observed when the antibodies formed large immune complexes with multivalent antigens, but not in a linear relation with size. The binding properties of monomeric mAb2 were identical with and without a bound monovalent antigen, indicating that antigen-binding alone does not induce measurable change in binding of antibodies to Fcgamma receptors. Dimerization is sufficient to show enhancement in the receptor binding. Given the wide distribution of the low-affinity Fcgamma receptors on immune effector cells, the increased affinities to aggregated IgG may lead to some biological consequences, depending on the subsequent signal transduction events. The SPR-based in vitro binding assay is useful in evaluating Fcgamma receptor binding of various species in antibody-based biotherapeutics.

Mesh:

Substances:

Year:  2009        PMID: 20065648      PMCID: PMC2759499          DOI: 10.4161/mabs.1.5.9631

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  46 in total

1.  The structure of a human type III Fcgamma receptor in complex with Fc.

Authors:  S Radaev; S Motyka; W H Fridman; C Sautes-Fridman; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

Review 2.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Authors:  E Koren; L A Zuckerman; A R Mire-Sluis
Journal:  Curr Pharm Biotechnol       Date:  2002-12       Impact factor: 2.837

3.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

4.  Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Authors:  Hiroaki Nagashima; Tomoya Tezuka; Wakako Tsuchida; Hiroaki Maeda; Junya Kohroki; Yasuhiko Masuho
Journal:  Mol Immunol       Date:  2008-03-18       Impact factor: 4.407

Review 5.  Fc receptors.

Authors:  J V Ravetch; J P Kinet
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

Review 6.  Fc receptors are major mediators of antibody based inflammation in autoimmunity.

Authors:  P Mark Hogarth
Journal:  Curr Opin Immunol       Date:  2002-12       Impact factor: 7.486

Review 7.  IgG-Fc receptors and the clinical relevance of their polymorphisms.

Authors:  M de Haas
Journal:  Wien Klin Wochenschr       Date:  2001-10-30       Impact factor: 1.704

Review 8.  Recognition of immunoglobulins by Fcgamma receptors.

Authors:  Sergei Radaev; Peter Sun
Journal:  Mol Immunol       Date:  2002-05       Impact factor: 4.407

9.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

Authors:  P Schuck
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

Review 10.  Fcgamma receptors in autoimmune diseases.

Authors:  G Fossati; R C Bucknall; S W Edwards
Journal:  Eur J Clin Invest       Date:  2001-09       Impact factor: 4.686

View more
  24 in total

1.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

2.  The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2015-02-06       Impact factor: 5.157

Review 3.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

4.  Evidence for intermolecular domain exchange in the Fab domains of dimer and oligomers of an IgG1 monoclonal antibody.

Authors:  Yin Luo; Stephen W Raso; Judith Gallant; Colleen Steinmeyer; Yasuko Mabuchi; Zhaojiang Lu; Clifford Entrican; Jason C Rouse
Journal:  MAbs       Date:  2017-06-07       Impact factor: 5.857

5.  Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Authors:  E M Moussa; J Kotarek; J S Blum; E Marszal; E M Topp
Journal:  Pharm Res       Date:  2016-04-01       Impact factor: 4.200

6.  Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm.

Authors:  Dan Boyd; Arpa Ebrahimi; Sarah Ronan; Brian Mickus; Matthew Schenauer; Jenny Wang; Darren Brown; Alexandre Ambrogelly
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

7.  Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.

Authors:  Yann Gallais; Natacha Szely; François-Xavier Legrand; Arnaud Leroy; Marc Pallardy; Isabelle Turbica
Journal:  Immunol Cell Biol       Date:  2016-10-07       Impact factor: 5.126

Review 8.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

9.  Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.

Authors:  Xiaoyi Yang; Abraham Kallarakal; Nirmala Saptharishi; Hengguang Jiang; Zhiwen Yang; Yueqing Xie; George Mitra; Xin Xiao Zheng; Terry B Strom; Gopalan Soman
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

Review 10.  Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.

Authors:  Kirsten M Baecher; Mandy L Ford
Journal:  Cancer Immunol Immunother       Date:  2021-07-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.